Outcomes of Peptide Receptor Radionuclide Therapy After Progression Following Hepatic Cytoreductive Operation for Neuroendocrine Tumors
- 10 June 2026
- journal article
- Published by Elsevier in The American Journal of Surgery
- Vol. 260, 117099
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United StatesJAMA Network Open, 2021
- Evaluation of the prognosis for N2 status in patients with small bowel neuroendocrine tumorsThe American Journal of Surgery, 2021
- Outcomes of cytoreductive operations for peritoneal carcinomatosis with or without liver cytoreduction in patients with small bowel neuroendocrine tumorsSurgery, 2021
- Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2020
- Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs)Surgery, 2019
- Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumorsSurgery, 2018
- Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United StatesJAMA Oncology, 2017
- Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy?Surgery, 2016
- Expanded criteria for carcinoid liver debulking: Maintaining survival and increasing the number of eligible patientsSurgery, 2014
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009